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Multiple studies evaluating non-small cell lung cancer disparities reveal male gender and African 
American race as independent predictors for poorer outcome. This study aims to evaluate the 
prognostic factors affecting survival of non-small cell lung cancer patients receiving radiation treatment 
at the University of Washington and to investigate whether race and gender disparities persist at the 
level of access to radiation treatment. Race, age, stage at presentation, radiation treatment length, and 
length of time from initial diagnosis to death or last follow-up were recorded and analyzed in a 
retrospective review of 372 patients receiving radiation treatment from 1994 - 2008. Of a final 372 
patients, 306 were Caucasian, 32 African American, 34 Asian American and 134 female, 238 male 
patients. Cox regression models showed male gender [hazard ratio (HR, 1.34) p-value 0.027] and stage 
at presentation [stage III: HR, 1.93, p-value .001, stage IV: HR, 2.46, P value < 0.001] were predictors for 
shorter survival. In these analyses, race had no significant effect on length of survival. These results 
suggest disparate origins of race and gender inequity in non-small cell lung cancer outcome, 
highlighting that race differences in lung cancer survival disappear at the level patients have access to 
radiation treatment. This supports the notion that gender survival differences are likely the result of 
biologic differences, while racial survival disparities are an issue of healthcare access- however, 
additional studies are needed to conclusively discern the etiology of these disparities. 
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INTRODUCTION 
 
Although cancer continues to be the leading cause of 
death in the world, treatment options are improving (Ou 
et al., 2008). It is important to include all segments of 
society in these advancements, but this proves to be only 
an ideal. The unequal distribution of cancer burden is well 
documented and the American Cancer Society and other 
institutions have committed themselves to the  elimination 
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of cancer disparity - a formidable task. The elimination of 
disparity is defined as a reduction in cancer incidence 
and mortality and an increase in cancer survival among 
socioeconomically disadvantaged people to levels 
comparable to those in the general population (Ward et 
al., 2004). As a result, in order to achieve this goal, the 
complex nature of health disparities must be investigated 
and as many contributing factors identified as possible. 
Ideas on the origins of racial health disparities are 
complex and controversial. Data show overall life 
expectancy is lower for African Americans than for other 
racial     and    ethnic    groups     in   the    United   States 
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(Bodenheimer and Grumbach, 2009).  
In fact, infant mortality rates among African Americans 
are more than double than those for whites. While 
socioeconomic status appears to be the dominant 
influence on health status, issues of access to 
healthcare, cultural barriers, and even racism are also 
thought to contribute (King and Wheeler, 2007). 
 
 
Overview of race disparities in cancer 
 
Health disparities in cancer incidence, treatment and 
survival are tumor specific and diverse in both origin and 
magnitude. Research of these disparities involves 
investigating possible biological and lifestyle differences 
between demographic groups, but also requires an 
examination of healthcare access, delivery, and the 
effects of poverty. As an example, breast cancer has 
been shown to be more aggressive in African American 
women, thus resulting in poorer survival in comparison to 
other races (Cunningham and Butler, 2004). Also, some 
research indicates that differences in tumor size and 
histological grade in African American women compared 
to non-Hispanic white women disappeared when 
controlling for the time-interval since last mammography 
(Smith-Bindman et al., 2006). Other studies have argued 
that the “major factor precluding [minority populations] 
from sharing equally in advances in cancer research is 
prevailing societal and institutional racism” (Shinagwa, 
2000). So in addition to adjusting treatment protocol in 
response to known biological differences in African 
American women, issues of health care delivery also 
need to be addressed in order to effectively remedy 
breast cancer survival differences. Similar multi-pronged 
problems result in disparities with regard to other 
cancers.  
In certain types of cancers, such as prostate cancer, 
race can be used as a prognostic indicator of outcome. 
Black men have been shown to have more aggressive 
prostatic tumors, a higher rate of metastasis, and a 
poorer survival rate than white men (Kim et al., 1995). 
However, if differences in patient, tumor and treatment 
factors are controlled, research shows that biological 
differences between races are unlikely to be responsible 
for a substantial portion of survival discrepancy with 
regard to all cancers (Wisnivesky et al., 2005).  
Another study found that the stage at which colon 
cancer is a diagnosed, accounts for more than half of the 
excess colon cancer mortality in African American versus  
Caucasian (Mayberry et al., 1995). Other studies have 
extended this finding to lung cancers as well (Akerley et 
al., 1993). 
 
 
Non-small cell lung cancer and race 
 
The present  study  focuses on non-small cell lung cancer 
 
 
 
 
disparity. Prior research has shown poorer survival in 
males and in African Americans, but has failed to clearly 
define the origins for these survival disparities (Gadgeel 
et al., 2001). Bach et al. pointed to differences in 
treatment in explaining racial differences, showing that 
African Americans with early stage NSCLC have lower 
rates of surgical resection (Bach et al., 1999). A study 
from the Department of Veterans Affairs in Vermont 
found similar results among late stage lung cancer 
patients, with a lower rate of prior tumor resection among 
African American patients, greater frequency of 
mediastinal lymph node involvement and metastases, 
and a lower frequency of prior radiation therapy (Akerley 
et al., 1993).  
However, this same study found no differences in 
intensity of treatment, time to progression, response to 
treatment, or overall survival among Caucasian versus 
African American once they entered the prospective 
study and received uniform treatment. Additional 
research has shown that when ensuring uniform staging, 
treatment, and socioeconomic status, overall survival 
rates for black and white patients with NSCLC were 
similar (Bryant and Cerfolio, 2008) and socioeconomic 
status has now been shown to be an independent 
prognostic factor for poorer outcomes in NSCLC survival 
(Ou et al., 2008). In effect, past research indicates that 
differences in lung cancer survival between racial groups 
are thus unlikely to be a result of genetic or biological 
causes, but rather an issue of healthcare access.  
 
 
Non-small cell lung cancer and gender 
 
Past research also indicates poorer survival in males 
compared to females with respect to non-small cell lung 
cancer (Cerfolio et al., 2006). Women have been shown 
to be more susceptible to tobacco carcinogens, but have 
a lower rate of fatal outcome compared to men with non-
small cell lung cancer (JAMA, 2006). These differences 
are independent of socioeconomic status. Ou et al. 
(2007) has also shown that male sex is an independent 
prognostic factor for poorer survival in stage I NSCLC 
patients. 
The present study investigates lung cancer survival 
disparities, with regard to both gender and race, by 
investigating survival in patients who received radiation 
treatment at the University of Washington. By restricting 
the data pool to non-small cell lung cancer patients with 
access to radiation treatment at a tertiary hospital, this 
study is in effect controlling for access to healthcare. 
Since all patients in the present study are at an equal 
level of healthcare access, the expectation is that there 
will be no racial disparity in survival, but a gender 
disparity in survival will persist due to its non-healthcare 
access etiology. In addition, stage of presentation of 
patients will be investigated, and although past research 
indicates  African  Americans are more likely to present at 
Khanal et  al.     31 
 
 
 
Table 1. Tabulations for NSCLC stages by race. 
 
Stage I or II (%) III (%) IV (%) Total 
Caucasian 49 (16) 142 (46) 115 (38) 306 
African American 3 (8) 16 (50) 13 (41) 32 
Asian/Pacific Islander 5 (15) 17 (50) 12 (35) 34 
Total 57 (15) 175 (47) 140 (38) 372 
 
 
 
Table 2. Estimated median survival times in days and stratified by race. 
 
Race Number of observations Number of deaths median survival 
Caucasian 306 209 498 
African American 32 19 608 
Asian/Pacific Islander 34 22 413 
 
 
 
a higher stage (Gadgeel et al., 2001), investigating 
patients at the same level of healthcare access should 
not show significant differences if issues of access to 
care are at the root of this disparity. Lastly, any difference 
between date of diagnosis and start of radiation treatment 
will be assessed to investigate possible disparities in 
healthcare access after initial consult at radiation 
oncology and the actual start of radiation treatment. 
 
 
MATERIALS AND METHODS 
 
A retrospective review of 372 patients who received radiation 
treatment for non-small cell lung cancer at the University of 
Washington from 1994 to 2008 was conducted. Complete cases 
were those patients who received the entirety of their radiation 
treatment at the University of Washington, and whose medical 
records included race, age, gender, stage of presentation, and 
length of time from initial diagnosis to death or last follow-up. 
All patients included in this study were staged, treated, and 
prescribed radiation doses per treatment guidelines at the time. 
Treatment planning was undertaken at the University of 
Washington Medical Center (UWMC) by staff radiation oncologists 
per specialty standard. 
Exposure in this study was defined as a non-small cell lung 
cancer diagnosis, which was biopsy proven, staged cancer for all 
patients in the study. End points included date of death or date of 
last follow-up. Date of death was obtained either directly through 
patient medical records, or through the social security death index. 
Patients without a date of death either from their medical chart or 
through the social security registry were considered to be still alive. 
For these patients, the date of their last follow-up at the University 
of Washington was coded and included in the analyses. 
Data was organized in Microsoft access, and statistical analyses 
were performed using The R project for statistical computing. To 
investigate disparities in stage of presentation, chi-squared tests 
were used to examine the significance of differences in the 
proportions of each stage between racial groups. A Cox 
proportional hazards model was used to evaluate survival, and 
included the following variables: age, race, gender and stage of 
presentation. A linear regression model adjusting for those same 
variables was used to investigate lag time from diagnosis to 
treatment. 
This study was approved by the Institutional Review Board at the  
University of Washington. 
RESULTS 
 
Of a total 372 patients, 306 were Caucasian, 32 were 
African American, and 34 were Asian/Pacific Islander. 
Among all patients, 57 presented with stage 1 or 2 
NSCLC, 175 at stage 3 and 140 at stage 4. These results 
are summarized in Table 1. No significant differences 
were found in the stage of presentation between 
Caucasians, African Americans and Asian/Pacific 
Islanders (P value < 0.89). 
Using the Kaplan Meier technique, median survival 
after diagnosis was estimated for Caucasians, African 
Americans, and Asian/Pacific Islanders at 498, 608, 413 
days respectively. These results, along with the number 
of deaths observed in each racial category are 
summarized in Table 2. Cox regression models revealed 
male gender [hazard ratio (HR, 1.34) P value < 0.027] 
and stage of cancer [stage III: HR, 1.93, P value < 0.001, 
stage IV: HR, 2.46, P value < 0.001] to be significant 
predictors of survival. Other variables in the Cox model 
such as age and race were not significant. Tables 3, 4 
and 5 summarize the results of the survival analyses. 
Lastly, an ANOVA test of the covariates from linear 
regression models was performed to determine which 
variables in the model account for a significant amount of 
variation of the time between diagnosis and treatment. In 
other words, the ANOVA test hoped to determine which 
variables in the logistic regression model significantly 
predicted a longer or shorter lag time from diagnosis to 
treatment. None of the variables in the model, which 
included race, stage, age, and gender, proved significant 
(Table 6).  
 
 
DISCUSSION 
 
Poorer survival was associated with gender but not race 
in the study population. These results are consistent with 
previous research on survival disparities of non-small cell 
lung cancer  patients. By  isolating a patient population at 
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Table 3. Summary of Cox regression coefficient. 
 
 Coefficient  Standard error of  P value Hazards ratio 
Stage III 0.66 0.20 0.001 1.93 
Stage IV 0.90 0.21 < 0.001 2.46 
Age 0.019 0.005 0.009 1.01 
Gender = male 0.30 0.13 0.027 1.34 
Race = African American - 0.11 0.24 0.65 0.905 
Race = Asian/Pacific Islander - 0.0112 0.23 0.96 0.99 
 
 
 
Table 4. Estimated median survival time in days and stratified by stage. 
 
Stage Number of observations Number of deaths Median survival 
I or II 57 31 1107 
III 175 119 450 
IV 140 100 371 
 
 
 
Table 5. Estimated median survival time in days and stratified by gender. 
 
 Number of observations Number of deaths Median survival 
Female 134 88 686 
Male 238 162 418 
 
 
 
Table 6. ANOVA decomposition of days to start treatment adjusted by stage, age and gender. 
 
Covariate Degrees of freedom Sum of squares Mean square error F-value P value 
Stage 2 34.66 17.33 7.48 < 0.001 
Age 1 0.22 0.22 0.09 0.76 
Gender 1 6.27 6.27 2.71 0.10 
Race 2 4.73 2.36 1.02 0.36 
Residuals 365 848.43 2.32   
Total 371 893.35    
 
 
 
a common level of healthcare access, it is possible to 
further investigate whether certain disparities are a result 
of a lack of access to healthcare. Akerly et al. (1993) was 
able to isolate a patient population at a similar level of 
access by designing a prospective study of patients who 
after a certain point all received treatment for their non-
small cell lung cancer at the VA hospital system. The 
present study shows a similar result to Akerly et al. 
(1993) with no racial survivability difference among 
patients with access to radiation treatment at a tertiary 
hospital. 
In addition, this study found that African American 
patients were no more likely than white patients to 
present with advanced stage disease. Akerly et al. (1993) 
used patients who all had advanced stage disease and 
was able to show greater rates of metastases among 
African American patients. However, in  this  study,  since 
any patient that received the entirety of their radiation 
treatment at a University of Washington hospital was 
included, patients encompassed both early and late stage 
lung cancers at presentation - and no significant 
differences were found among black and white patients. 
All patients in our study had access to, and were able to 
complete a full course of treatment at the University of 
Washington. Thus, finding no difference in stage of 
presentation between racial groups indicates that 
healthcare access could be at the root of this disparity. 
The analysis of time elapsed between diagnosis and 
treatment was performed in hopes of further investigating 
possible treatment differences between the races, but 
none were found. This provides further evidence of equal 
healthcare access between racial groups in this study, as 
an increased lag time between diagnosis and initiation of 
treatment  in one racial group versus another could result 
  
 
 
from disparate access to healthcare. 
Being male was associated with a 1.34-fold greater risk 
of death compared to female patients. Recent research 
has shown somewhat similar results, with men 
maintaining a 20% increased risk compared to women 
following a diagnosis of NSCLC (Visbal et al., 2004). This 
same study found that survival for men with NSCLC 
stage Ia was similar to that of women with stage Ib 
NSCLC, and that men with stage IIa had outcomes 
similar to women with stage IIb. Essentially men with a 
given NSCLC stage had survival equivalent to women 
with the next stage of NSCLC.  
Current research indicates a genetic predisposition to 
NSCLC (Visbal et al., 2004; Nakamura et al., 2000; 
Sellers et al., 1992) Cellular and immunological markers 
have been shown to not only vary with NSCLC stage, but 
also with patient demographic characteristics such as 
age and gender as well. Differing immunological markers 
not only suggest varying biological response to NSCLC 
between men and women, which could be the basis of 
differential survival, but it also has important treatment 
potential as well (Nakamura et al., 2000). 
It logically follows that those patients who experience 
worse outcomes primarily as a result of their lack of 
healthcare access would not be included in the study 
population, as they would be less likely to have ongoing 
access to an academic hospital in order to complete their 
full course of radiation treatment. Gender was found to be 
an independent prognostic factor in NSCLC outcome 
independent of healthcare access. However, isolating a 
patient population at an equal level of healthcare access 
eliminated known racial differences in survival. The 
results of this study indicate that healthcare access may 
be an important confounding factor in disparate outcomes 
in NSCLC. 
A limitation of our study is the small number of African 
American patients. Given the small number of African 
Americans (n = 32), a sensitivity analysis was performed 
to investigate the size of a hazard ratio detectable given a 
power of 0.8. In this study, given the proportion of 
Caucasians to African Americans, it would be possible to 
detect a hazards ratio of 1.77 with 0.8 power, but nothing 
smaller. In terms of median survival, the median survival 
for African Americans needed to have been 1.77*498 = 
881 days or greater or 281 days or less than Caucasian 
patients to detect a difference. As an example of prior 
research results in racial survival differences, Gadgeel et 
al. (2001) found that African Americans in comparison to 
whites with local stage NSCLC in the Detroit metro area 
were at a 1.24 relative risk of death, P < 0.0001 (Gadgeel 
et al., 2001). It is worth noting that our study found a 
slight non-significant survival advantage among African 
American patients, HR 0.905. It is thus possible only to 
say that our results are trending toward no racial 
differences in survival. Further studies, with more robust 
power would allow for more definitive conclusions. 
Of note, the small number of African American subjects 
Khanal et  al.     33 
 
 
 
included in this study may reflect the larger issue of 
disparate access. Our study’s inclusion criteria of cases 
from 1994 to 2008 reflected only those patients that 
completed their entire course of radiation therapy at the 
University of Washington Medical Center (UWMC). It is 
possible that the small number of African American 
patients that did complete their entire radiation course at 
UWMC simply reflects the barriers to accessing radiation 
therapy at a tertiary care facility among members of their 
racial group. However, further studies are needed to 
make this conclusion definitively.  
Another potential limitation of this study is the length of 
time this study spans, 1994 to 2008. There has been 
great changes in radiation techniques and treatment 
modality in these fourteen years. However, there were no 
differences between genders or races, in time period 
from which they were treated. Nonetheless, it is feasible 
that non-significant differences in the date of each case 
may have altered results. Also, though we did include 
patient prognostic factors such as stage of cancer and 
age of patient into our Cox model, other patient 
prognostic factors such as nutrition, co-morbid medical 
conditions were not coded and thus not included in our 
calculation. It is possible that these other prognostic 
factors could have accounted for some of the survival 
differences seen between male and female patients. 
Further investigation will be needed to characterize the 
root of gender differences in our study. 
The implications of the present study’s results are 
important to consider when assessing the problems of 
healthcare in the United States. The trend of the present 
study’s findings shed light on the arguably serious issues 
of disparate healthcare access among certain segments 
of our society. It is well known that regions in the nation 
with higher health care spending do not have better 
outcomes (Fisher, 2003) and issues of healthcare access 
may very well be a significant contributing factor for this 
discrepancy.  
Studies in the past have suggested institutionalized 
racism, including cultural barriers between physicians 
and patients, as a reason for racial disparities in health 
(King and Wheeler, 2007). It is well known that 
neighborhoods that have high proportions of African 
American or Latino residents have far fewer physicians 
practicing (Komaromy, 2006). In addition, it is possible 
that unconscious forms of discrimination may continue to 
enter interactions between patients and their caregivers 
and influence access to care for minorities (Van Ryn, 
2002). However, the trends of the present study’s 
findings do not support this, as survival was equal when 
access among patients was equal. Further research is 
necessary to pinpoint the exact biological etiology of the 
gender disparity in non-small cell lung cancer survival. 
With regard to the racial disparity of lung cancer 
outcome, further research into the specific nature of 
disparate access to healthcare among African Americans 
is urgently necessary in  order  to  effectively  combat this 
34    J. Cancer Res. Exp. Oncol. 
 
 
 
problem. 
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